Port RE - Search Results

1

Conditions of drug delivery within solid tumors, and noninvasive methods for studies in humans.

Port RE. Port RE. Int J Clin Pharmacol Ther. 1997 Feb;35(2):78-9. Int J Clin Pharmacol Ther. 1997. PMID: 9147714 Review. No abstract available.

2

Contrast-enhanced MR imaging in the indirect monitoring of drug release from an interstitial depot.

Port RE, Schuster C, Port CR, Bachert P. Port RE, et al. Among authors: port cr. Int J Clin Pharmacol Ther. 2005 Dec;43(12):605-6. doi: 10.5414/cpp43605. Int J Clin Pharmacol Ther. 2005. PMID: 16372536 No abstract available.

3

Noninvasive methods to study drug distribution.

Port RE, Wolf W. Port RE, et al. Invest New Drugs. 2003 May;21(2):157-68. doi: 10.1023/a:1023569328717. Invest New Drugs. 2003. PMID: 12889737 Review.

4

The influence of elevated liver function parameters on the pharmacokinetics of doxorubicin and epirubicin--a population based pharmacokinetic study of CESAR-APOH. Central European Society for Anticancer Drug Research. Working Group for Pharmacology in Oncology and Hematology.

Müller HJ, Grubert M, Hilger R, Richly H, Port R, Scheulen M, Mross K; CESAR-APOH. Müller HJ, et al. Int J Clin Pharmacol Ther. 2002 Dec;40(12):575-7. doi: 10.5414/cpp40575. Int J Clin Pharmacol Ther. 2002. PMID: 12503820 Clinical Trial. No abstract available.

5

Non-parametric mixed effects modeling with NPAG: hematopoietic response to erythropoietin in children.

Port RE. Port RE. Int J Clin Pharmacol Ther. 2004 Mar;42(3):185-6. doi: 10.5414/cpp42185. Int J Clin Pharmacol Ther. 2004. PMID: 15049440 No abstract available.

6

Noninvasive determination of the arterial input function of an anticancer drug from dynamic PET scans using the population approach.

Kissel J, Port RE, Zaers J, Bellemann ME, Strauss LG, Haberkorn U, Brix G. Kissel J, et al. Among authors: port re. Med Phys. 1999 Apr;26(4):609-15. doi: 10.1118/1.598560. Med Phys. 1999. PMID: 10227363

7

Pharmacokinetic analysis of sparse in vivo NMR spectroscopy data using relative parameters and the population approach.

Port RE, Schlemmer HP, Bachert P. Port RE, et al. Eur J Clin Pharmacol. 1994;47(2):187-93. doi: 10.1007/BF00194971. Eur J Clin Pharmacol. 1994. PMID: 7859808

8

The influence of liver metastases on the pharmacokinetics of doxorubicin---a population-based pharmacokinetic project of the CESAR-APOH.

Müller HJ, Port RE, Grubert M, Hilger RA, Scheulen M, Mross K; CESAR-APOH. Müller HJ, et al. Among authors: port re. Int J Clin Pharmacol Ther. 2003 Dec;41(12):598-9. doi: 10.5414/cpp41598. Int J Clin Pharmacol Ther. 2003. PMID: 14692710 Clinical Trial. No abstract available.

9

Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of the rat.

Stüben J, Port R, Bertram B, Bollow U, Hull WE, Schaper M, Pohl J, Wiessler M. Stüben J, et al. Cancer Chemother Pharmacol. 1996;38(4):355-65. doi: 10.1007/s002800050495. Cancer Chemother Pharmacol. 1996. PMID: 8674159

10

Local disposition kinetics of floxuridine after intratumoral and subcutaneous injection as monitored by [19F]-nuclear magnetic resonance spectroscopy in vivo.

Port R, Hanisch F, Becker M, Bachert P, Zeller J. Port R, et al. Cancer Chemother Pharmacol. 1999;44(1):65-73. doi: 10.1007/s002800050946. Cancer Chemother Pharmacol. 1999. PMID: 10367751

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters